Skip to main content
OSTI.GOVU.S. Department of Energy Office of Scientific and Technical Information
U.S. Department of Energy
Office of Scientific and Technical Information
 

Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition

Journal Article · · Nature Communications
 [1];  [2];  [3];  [2];  [2];  [2];  [2];  [2];  [2];  [3]
  1. Harvard Medical School, Boston, MA (United States); Dana-Farber Cancer Inst., Boston, MA (United States); DOE/OSTI
  2. Novartis Inst. for Biomedical Research, Cambridge, MA (United States)
  3. Harvard Medical School, Boston, MA (United States); Dana-Farber Cancer Inst., Boston, MA (United States)
+ Show Author Affiliations
Activating mutations in PTPN11, encoding the cytosolic protein tyrosine phosphatase SHP2, result in developmental disorders and act as oncogenic drivers in patients with hematologic cancers. The allosteric inhibitor SHP099 stabilizes the wild-type SHP2 enzyme in an autoinhibited conformation that is itself destabilized by oncogenic mutations. Here, we report the impact of the highly activated and most frequently observed mutation, E76K, on the structure of SHP2, and investigate the effect of E76K and other oncogenic mutations on allosteric inhibition by SHP099. SHP2E76K adopts an open conformation but can be restored to the closed, autoinhibited conformation, near-identical to the unoccupied wild-type enzyme, when complexed with SHP099. SHP099 inhibitory activity against oncogenic SHP2 variants in vitro and in cells scales inversely with the activating strength of the mutation, indicating that either oncoselective or vastly more potent inhibitors will be necessary to suppress oncogenic signaling by the most strongly activating SHP2 mutations in cancer.
Research Organization:
Argonne National Laboratory (ANL), Argonne, IL (United States); Advanced Photon Source (APS)
Sponsoring Organization:
USDOE Office of Science (SC), Basic Energy Sciences (BES). Scientific User Facilities Division; National Institute of Health (NIH)
DOE Contract Number:
AC02-06CH11357
OSTI ID:
1481293
Journal Information:
Nature Communications, Journal Name: Nature Communications Journal Issue: 1 Vol. 9; ISSN 2041-1723
Publisher:
Nature Publishing Group
Country of Publication:
United States
Language:
ENGLISH

References (30)

Therapeutic Potential of Targeting the Oncogenic SHP2 Phosphatase journal July 2014
PD-1/SHP-2 Inhibits Tc1/Th1 Phenotypic Responses and the Activation of T Cells in the Tumor Microenvironment journal December 2014
Off-target inhibition by active site-targeting SHP2 inhibitors journal August 2018
SHP2 phosphatase as a novel therapeutic target for melanoma treatment journal September 2016
The ‘Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling journal June 2003
Crystal structure of human protein tyrosine phosphatase SHP-1 in the open conformation journal July 2011
The tyrosine phosphatase Shp2 (PTPN11) in cancer journal February 2008
Features and development of Coot journal March 2010
Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia journal April 2003
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases journal June 2016
Potent Stimulation of SH-PTP2 Phosphatase Activity by Simultaneous Occupancy of Both SH2 Domains journal February 1995
Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome journal November 2001
Dual Allosteric Inhibition of SHP2 Phosphatase journal January 2018
Phaser crystallographic software journal July 2007
Drug–target residence time and its implications for lead optimization journal August 2006
Crystal Structure of the Tyrosine Phosphatase SHP-2 journal February 1998
Identification of an allosteric benzothiazolopyrimidone inhibitor of the oncogenic protein tyrosine phosphatase SHP2 journal December 2017
Liquid-chromatography-coupled SAXS for accurate sizing of aggregating proteins journal June 2004
Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor journal July 2016
PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs journal September 2015
Structural and Functional Consequences of Three Cancer-Associated Mutations of the Oncogenic Phosphatase SHP2 journal April 2016
Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations journal February 2005
Functions of Shp2 in cancer journal June 2015
WGE: a CRISPR database for genome engineering: Fig. 1. journal May 2015
Drugging the Undruggable: Therapeutic Potential of Targeting Protein Tyrosine Phosphatases journal December 2016
New developments in the ATSAS program package for small-angle scattering data analysis journal March 2012
XDS journal January 2010
Genome engineering using the CRISPR-Cas9 system journal October 2013
Role of SH-PTP2, a protein-tyrosine phosphatase with Src homology 2 domains, in insulin-stimulated Ras activation. journal October 1994
Exploiting structure similarity in refinement: automated NCS and target-structure restraints in BUSTER journal March 2012

Similar Records

Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2
Journal Article · Tue Oct 30 00:00:00 EDT 2018 · Nature Communications · OSTI ID:1624118
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
Journal Article · Wed Jun 29 00:00:00 EDT 2016 · Nature (London) · OSTI ID:1404986
Structural and Functional Consequences of Three Cancer-Associated Mutations of the Oncogenic Phosphatase SHP2
Journal Article · Mon Apr 11 00:00:00 EDT 2016 · Biochemistry · OSTI ID:1249241

Related Subjects

Chemical biology
X-ray crystallography